Huntington's Disease (HD) is one of nine neurodegenerative disorders caused by polyglutamine (polyQ) domain expansion. There is currently no cure nor effective treatment available for HD. In our C. elegans model of polyQ (CGC # 3360), the N-terminus of the toxic expanded human huntingtin protein causes age dependent degeneration of ASH neurons. We are developing drug efficacy assays to test possible therapeutic agents and assess their impact on polyQ mediated neurodegeneration in C. elegans. Drug studies should also provide insight into the contributions of different cellular pathways to the disease process. Our first assay format used animals that also carry a mutation in
pqe-1, a previously identified, genetic enhancer of polyQ toxicity (CGC # 5585). In
pqe-1 mutant animals, the vast majority of ASH neurons undergo cell death before the animals reach adulthood. L1s were incubated with drugs and food for two or three days before the death of ASH neurons was evaluated. We identified several compounds, but some therapeutic doses also slowed growth. To assess the impact of slower growth on polyQ toxicity, we developed a second assay that was independent of growth. ASH cell death increases over time in arrested L1
pqe-1 animals. L1s were incubated with drugs in the absence of food for one or two days before the death of ASH neurons was evaluated. We tested several compounds in this new assay format and found that LiCl and mithramycin suppressed neurodegeneration. Both compounds have similar effects in other HD models. LiCl is a GSK-3 inhibitor that has been shown to reduce polyQ toxicity in cell culture (Carmichael J et al, 2002). Mithramycin binds to GC rich regions of DNA and has been shown to reduce polyQ toxicity in a mouse HD model (Ferrante et al, 2004). Currently, we are developing an additional assay utilizing aged animals with normal
pqe-1 function to further evaluate what effect these compounds have on the age dependent degeneration associated with expression of the toxic expanded human huntingtin protein. We believe that our drug assays provide an efficient means of identifying therapeutic agents for further testing in vertebrate models of polyQ diseases.